MedTrace Logo

Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy

NCT02238444 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-01-02

No results posted yet for this study

Summary

The purpose of this study is to determine whether Warfarin Anticoagulation are effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients with Hypersplenism after Laparoscopic Splenectomy.

Conditions

  • Cirrhosis
  • Hypertension
  • Venous Thrombosis
  • Status; Splenectomy

Interventions

DRUG

Warfarin

From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.

DRUG

Dipyridamole

From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.

DRUG

Aspirin

From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.

DRUG

Low Molecular Weight Heparin

From postoperative day 3, Patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.

Sponsors & Collaborators

  • Yangzhou University

    lead OTHER

Principal Investigators

  • Dou-Sheng Bai, MD · Clinical Medical College of Yangzhou University

  • Guo-Qing Jiang, MS · Clinical Medical College of Yangzhou University

  • Ping Chen, MD · Clinical Medical College of Yangzhou University

  • Sheng-Jie Jin · Clinical Medical College of Yangzhou University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-01
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02238444 on ClinicalTrials.gov